FDA Inspection 1225621 — Guangzhou Baiyunshan Jingxiutang Pharmaceutical Co. Ltd.
The FDA completed an inspection of Guangzhou Baiyunshan Jingxiutang Pharmaceutical Co. Ltd. on December 8, 2023 in Foshan. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). Product area: Drugs.
Inspection Details
- Classification
- Official Action Indicated (OAI) (OAI)
- End Date
- December 8, 2023
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Foshan (China)